Galena Biopharma, Inc. GALE
Set alert
No live quote for GALE yet.
- Open
- 0.291
- Prev close
- 0.262
- Mkt cap
- 399.23K
- Vol
- 20.37M
- Avg vol
- 789.02K
- EPS
- -1.11
- P/E
- -0.24
- Div yield
- 0.00%
More statistics
- Low
- 0.26
- High
- 0.40
- Forward P/E
- -0.31
- Beta
- 2.34
- Short ratio
- 7.04
- Inst. own
- 23.13%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 163.85
- 200-d avg
- 40.06
- 1y target
- 8.00
Key statistics
- Market cap
- 399.23K
- Enterprise value
- 12.56M
- Trailing P/E
- -0.24
- Forward P/E
- -0.31
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.75
- EPS (TTM)
- -1.11
- Beta
- 2.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -8.13M
- Total cash
- 12.91M
- Total debt
- 12.17M
- Return on equity
- -90.82%
- Shares outstanding
- 1.52M
- Short % of float
- 10.17%
- 50-day average
- 163.85
- 200-day average
- 40.06
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.15.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 5, 2017 | FBR Capital | down | — | Market Weight |
| Feb 1, 2017 | Maxim Group | down | — | Hold |
| Jun 28, 2016 | Raymond James | down | — | Market Perform |
| Mar 10, 2016 | Roth Capital | main | — | Buy |
| Dec 7, 2015 | Cantor Fitzgerald | up | — | Hold |
| Nov 11, 2015 | Oppenheimer | up | — | Outperform |
About Galena Biopharma, Inc.
Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer. In addition, the company develops GALE-301 and GALE-302 for ovarian, endometrial, and breast cancers. It has strategic development and commercialization partnership with Dr. Reddys Laboratories Ltd. for NeuVax in breast and gastric cancers. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in San Ramon, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- galenabiopharma.com
News
Your note
Sign in to keep a note on GALE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHTON WILLIAM | Director | Acquisition (Non Open Market) | Oct 9, 2017 | 38,154 |
| EINHORN IRVING M. | Director | Acquisition (Non Open Market) | Oct 9, 2017 | 34,690 |
| GRAY MARY ANN | Director | Acquisition (Non Open Market) | Oct 9, 2017 | 39,167 |
| HILLSBERG SANFORD | Director | Acquisition (Non Open Market) | Oct 9, 2017 | 56,950 |
| KRYLOV ALEKSEY N. | Officer | Ownership Statement | Dec 28, 2017 | 0 |
| LOPEZ FABIO | Director | Acquisition (Non Open Market) | Dec 28, 2017 | 0 |